Open Access

Japanese Journal of Gastroenterology(ISSN 2832-4870)

Anemia in inflammatory bowel disease patients: identification and management

Victoria Mückea

Corresponding author

Victoria Mückea,
J. W. Goethe University Hospital, Frankfurt, Germany; Addenbrooke's Hospital, University of Cambridge, Cambridge, UK; University Hospital Münster, Münster, Germany

Received Date: June 19, 2022
Accepted Date: June 20, 2022
Published Date: July 20, 2022

Abstract

Weakness addresses perhaps of the most successive confusion in fiery gut illness (IBD) and seriously impedes the personal satisfaction of impacted patients. The etiology of pallor in IBD patients can be multifactorial, frequently including a blend of lack of iron (ID) and sickliness of ongoing illness (ACD). Albeit current rules suggest evaluating for and treatment of paleness in IBD patients, current observational information propose that it actually remains underdiagnosed and undertreated. Other than fundamental lab boundaries (for example mean corpuscular volume, reticulocyte count, serum ferritin, transferrin immersion, and so forth), the grouping of dissolvable transferrin receptor (sTfR) and novel boundaries like the sTfR/log ferritin record can direct the difficult errand of separating among ID and ACD. Once distinguished, reasons for iron deficiency ought to be dealt with appropriately. This audit sums up our ongoing comprehension of sickliness in IBD patients, including the hidden pathology, symptomatic methodologies and fitting frailty therapy regimens.

Key words

Inflammatory bowel disease, anemia, iron deficiency

Introduction

Provocative entrail sickness (IBD), including Crohn's illness (Cd) and ulcerative colitis (UC), addresses a range of ongoing, transmitting issues of the gastrointestinal lot of obscure etiology [1,2]. Other than side effects essentially coming about because of digestive aggravation, IBD patients can foster different extra-gastrointestinal indications [3]. Weakness gives off an impression of being one of the most incessant intricacies of IBD [4,5]. Revealed pervasiveness rates are exceptionally factor and may approach up to 74% [4,6]. Heterogeneity in revealed rates to some extent reflects inadequately normalized meanings of frailty. Albeit the World Wellbeing Association (WHO) paleness rules [7] are broadly acknowledged, they have been addressed based on contrasts in nationality or neighborhood climate [8,9].

Moreover, in a new study across European nations, Stein et al uncovered that distinctions between understanding companions might add to wandering information. For instance, while announced predominance rates among short term patients range up to 16%, comparative information for hospitalized patients surpass 65% [10,11]. A new meta-examination of individual patient information from 2192 European patients decided the general pervasiveness of weakness in IBD patients to be 24%, with a detailed event of extreme pallor in 2.75% of patients dissected. In a similar report, the general pervasiveness was higher in Cd than in UC patients [12].Unfortunately, over the course of the last many years sickliness in IBD has gotten little consideration [13], reflected maybe in just negligible inclusion in previous worldwide rules for the administration of IBD [14]. Conversely, as of late the point has moved into the spotlight, since there is a developing group of proof that pallor assumes a vital part in influencing IBD patients' personal satisfaction (QOL). In 2014, Danese et al broke down pallor related side effects from an IBD patient's point of view [15].
Side effects broadly detailed by the 613 members included weariness, shortcoming, troubles in concentrating, burdensome state of mind, windedness, and dozing challenges. Patients impacted by weariness revealed a significant adverse consequence on day to day existence, including proactive tasks, efficiency and home life (76%, 63% and 60%, separately). A few different investigations have affirmed that Divisions of aInternal Medication 1, J.W. Goethe College Clinic, Frankfurt, Germany (Victoria Mücke, Marcus M. Mücke); bMedicine, Addenbrooke's Medical clinic, College of Cambridge, Cambridge, UK (Tim Raine); cMedicine B, College Clinic Münster, Münster, Germany (Dominik Bettenworth)

Pathophysiology of anemia in IBD

Anemia is a systemic consequence or extra-intestinal manifestation that can have a variety of causes in IBD patients, but is often brought on by a concomitant ID and anaemia of chronic illness (ACD) [21]. It is common knowledge that many IBD patients go on to acquire ID. Iron demand and absorption become out of balance as a result of chronic intestinal blood loss, dietary restrictions, and/or iron malabsorption brought on by mucosal inflammation or surgical colon resections (particularly in CD patients) [4,11,22]. Iron is a crucial mineral that is primarily contained in haemoglobin (Hb). Following intake,

dietary iron is changed from its ferric (Fe3+) form to its ferrous (Fe2+) form, where it is mostly absorbed via the divalent metal transporter at the apical surface of enterocytes in the duodenum.

Although animal heme, which is taken up into cells via a poorly known mechanism and destroyed to liberate bonded iron, is a substantial supplemental source of iron in the diet despite the fact that dietary iron is poorly absorbed. Iron is then transferred via the basolateral membrane using a specific ferroportin channel before being oxidised back to Fe3+. Transferrin binds almost all of the elemental iron in the circulation, which distributes it throughout the body [11,23]. Hepcidin, a peptide mostly generated in the liver, plays a critical role in controlling iron absorption [24].

Non-ID anemia in IBD patients

As previously mentioned, there are a number of other significant factors that can contribute to Hb deficiency in IBD patients. Measurements of vitamin B12 and folic acid levels should be made at screening visits, particularly in cases with macrocytic anaemia [44]. Additionally, myelosuppressive drugs such thiopurines and sulfasalazine should always be taken into account while doing an anaemic diagnostic workup [49,52].

Treatment of anemia in IBD

Therapeutic therapies aiming to normalise Hb levels play a critical role in the clinical care of IBD patients because anaemia adversely affects patients' QOL and raises disease severity and mortality rates [61]. Anemia in IBD patients should be recognised by doctors, and the underlying causes should be treated.

Iron therapy in IBD

In patients with proven ID anaemia, recent guidelines strongly advise iron supplementation [11,67,68]. Final therapeutic objectives are thought to be the restoration of iron reserves and the normalisation of haemoglobin levels. More specifically, appropriate treatment responses are defined as a Hb rise of >2 g/dL and a transferrin saturation of >30% within 4 weeks [11,69]. Clinical trials should be conducted to further investigate iron supplementation in IBD patients without obvious anaemia, especially in terms of treatment tolerance. The amounts of elemental and heme iron found in a typical diet are often sufficient. As previously mentioned, the inflammation of the mucosa in patients with active IBD causes maldigestion, malabsorption, and changes in eating habits [33,70,71], which may exacerbate ID and make exclusive nutritional supplementation impractical.

Nevertheless, patients with IBD who have mild disease activity and mild anaemia may benefit from oral iron replacement [72,73]. Many doctors prefer oral iron substitution as first-line therapy because to its widespread availability, low cost, and well-established safety profile. Ferrous fumarate (325 mg tablets contain 106 mg of elemental iron per tablet), ferrous sulphate (325 mg tablets contain 65 mg of elemental iron per tablet), and ferrous gluconate (325 mg tablets contain 65 mg of elemental iron per tablet) are three commonly used oral iron supplements (325 mg tablets containing 36 mg elemental iron per tablet). Oral supplementation must be assessed for effectiveness and tolerability, nevertheless, in light of numerous reports of adverse events [74] and further mucosal damage [72] in IBD patients receiving oral iron replacement therapy [75–77]. Trials on animals show that oral and rectal Through the increased synthesis of proinflammatory cytokines such IL-1, IL-6, TNF-, and IFN-, iron ingestion can result in a worsening of disease activity [78]. This may be related to an increase in flux in the traditional Fe2+-catalyzed Fenton reaction, which causes neutrophils in the mucosa to produce reactive oxygen species [79]. Because it is often well accepted by patients [15], intravenous iron supplementation is still preferred in IBD patients with ID anaemia, especially in cases of severe anaemia (Hb10 g/L), insufficient response to or intolerance of oral supplementations, or both [80,81]. Additionally, iron given intravenously has no negative effects on IBD patients' disease activity [80, 82].

Early studies used contemporary ferric iron preparations like Ferinject® and Monofer® (iron isomaltoside) (ferric carboxymaltose) were effective and well tolerated in terms of acute toxicity profile, effectiveness, and tolerance in patients with IBD. In terms of lower incidence of anaphylactoid responses, recent non-dextran intravenous formulations appear to be superior than treatments containing elemental iron complexed with dextrans. In actuality, this means that non-dextran formulations can be administered more quickly and without having to worry about applying a test dose [73,83-85]. The Ganzoni formula, however commonly used in the past to calculate iron needs and dosage, has come under fire for being cumbersome, unreliable, and imprecise [21]. A more modern method of calculating total iron has been put out, and it offers a straightforward and effective dosing schedule. Despite the fact that this strategy has onlyPhysicians have widely embraced it for use with other intravenous iron supplements after it was studied for the dose of intravenous ferric carboxymaltose.

Therapy of ACD in IBD

IBDOptimization of IBD treatment should be the main focus of treatment for ACD after diagnosis and treatment of any concurrent ID. This will help regulate the disease's activity. Concurrent infections, inflammatory conditions, or cancers should also be taken into account and treated as needed [21]. Additionally, the administration of erythropoietin-stimulating medications in addition to intravenous iron supplementation may be beneficial in treating ACD anaemia [5,90,91]. Erythropoietin has also been demonstrated in certain trials to lessen intestinal inflammation and to encourage epithelial tissue regeneration [92]. Additionally, anti-TNF medication may be necessary to support bone marrow output in TNF-induced bone marrow suppression [93].

Concluding remarks

IBD patients typically get ID anaemia. Therefore, all IBD patients should undergo routine screening for ID and ID anaemia (in accordance with the severity of the disease). The identification of decreasing Hb levels necessitates a more thorough diagnostic anaemia workup, whereas complete blood count, serum ferritin, and CRP value serve as an adequate screening benchmark. Iron replacement is still necessary in IBD patients with ID anaemia, and the benefits and drawbacks of oral and intravenous formulations should be carefully considered.

References

1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet2012;380:1590-1605.

2. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-1619.

3. Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol2013;10:585-595.

4. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006;24:1507-1523.

5. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008;103:1299-1307.

6. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004;116 Suppl 7A:44S-49S.

7. Nutritional anaemias. Report of a WHO scientific group. Wo r l d Health Organ Tech Rep Ser 1968;405:5-37.

8. Patel KV, Harris TB, Faulhaber M, et al. Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood 2007;109:4663-4670.

9. Beutler E, Waalen J. The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration? Blood2006;107:1747-1750.

10. Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009;15:4659-4665.

11. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010;7:599-610.

12. Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis 2014;20:936-945.

13. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis 2000;6:142-150; discussion 151.

14. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53 Suppl 5:V1-16.

15. Danese S, Hoffman C, Vel S, et al. Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn's and Ulcerative Colitis Association's online survey. Eur J Gastroenterol Hepatol 2014;26:1385-1391.

16. Pizzi LT, Weston CM, Goldfarb NI, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006;12:47-52.

17. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis2006;12:123-130.

18. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis2009;15:1485-1491.

19. Blumenstein I, Dignass A, Vollmer S, Klemm W, Weber-Mangal S, Stein J. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. JCrohns Colitis 2014;8:1308-1314.

20. Stein J, Bager P, Befrits R, et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol2013;25:1456-1463.

21. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015;9:211-222.

22. Murawska N, Fabisiak A, Fichna J. Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: Pathophysiology, diagnosis, and treatment. Inflamm Bowel Dis2016;22:1198-208.

23. Anderson GJ. Non-transferrin-bound iron and cellular toxicity. J Gastroenterol Hepatol 1999;14:105-108.

24. Atanasiu V, Manolescu B, Stoian I. Hepcidin—central regulator of iron metabolism. Eur J Haematol 2007;78:1-10.

25. Besson-Fournier C, Latour C, Kautz L, et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood2012;120:431-439.

26. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. JClin Invest 2004;113:1271-1276.

27. Demirag MD, Haznedaroglu S, Sancak B, et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med 2009;48:421-426.

28. Hohaus S, Massini G, Giachelia M, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. JClin Oncol2010;28:2538-2543.

29. Tsuchiya K, Nitta K. Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther Apher Dial 2013;17:1-8.

30. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.

31. Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood2006;107:4142-4148.

32. Basseri RJ, Nemeth E, Vassilaki ME, et al. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. JCrohns Colitis 2013;7:e286-e291.

33. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006;12:1101-1106.

34. Weiss G, Goodnough LT. Anemia of chronic disease. NEngl J Med2005;352:1011-1023.

35. Roodman GD, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp Hematol 1987;15:928-935.

36. Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 1995;85:989-996.

37. Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 1997;89:1430-1439.

38. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. JInterferon Cytokine Res 1998;18:555-559.

39. Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood2006;107:2702-2704.

40. Wang CQ, Udupa KB, Lipschitz DA. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. JCell Physiol1995;162:134-138.

41. Libregts SF, Gutiérrez L, de Bruin AM, et al. Chronic IFN-γ production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood 2011;118:2578-2588.

42. Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998;91:1235-1242.

43. Felli N, Pedini F, Zeuner A, et al. Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. JImmunol 2005;175:1464-1472.

44. Bermejo F, Algaba A, Guerra I, et al. Should we monitor vitamin b12 and folate levels in Crohn's disease patients? Scand J Gastroenterol 2013;48:1272-1277.

45. Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B(12) deficiency in pa-

tients with Crohn's disease. Inflamm Bowel Dis 2008;14:217-223.

46. Ward MG, Kariyawasam VC, Mogan SB, et al. Prevalence and risk factors for functional vitamin B12 deficiency in patients with Crohn's disease. Inflamm Bowel Dis 2015;21:2839-2847.

47. Yakut M, Ustün Y, Kabaçam G, Soykan I. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med 2010;21:320-323.

48. M'Koma AE. Follow-up results of hematology data before and after restorative proctocolectomy. Clinical outcome. Dis Colon Rectum 1994;37:932-937.

49. Gisbert JP, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008;103:1783-1800.

50. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006;79-80:153-170.

51. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983;28:833-842.

52. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-539.

53. Cappellini MD, Motta I. Anemia in clinical practice-definition and classification: Does hemoglobin change with aging? Semin Hematol 2015;52:261-269.

54. Artz A, Dong X. Defining anemia by race using epidemiologic data. Blood 2008;111:2941.

55. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:513-519.

56. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. NEngl J Med 1999;340:448-454.

57. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 2000;37:93-130.

58. Dubois RW, Goodnough LT, Ershler WB, Van Winkle L, Nissenson AR. Identification, diagnosis, and management of anemia in adult ambulatory patients treated by primary care physicians: evidence-based and consensus recommendations. Curr Med Res Opin 2006;22:385-395.

59. Voudoukis E, Karmiris K, Oustamanolakis P, et al. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. Eur J Gastroenterol Hepatol2013;25:1212-1216.

60. Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol2001;96:2296-2298.

61. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190-1197.

62. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003;329:9-22.

63. Oustamanolakis P, Koutroubakis IE. Soluble transferrin receptor-ferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. Inflamm Bowel Dis2011;17:E158-E159.

64. Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia. A meta-analysis. Am J Clin Pathol2012;138:642-649.

65. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol2011;86:923-927.

66. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Niniraki M, Kouroumalis EA. Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Ann Gastroenterol 2011;24:108-114.

67. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-1553.

68. Van Assche G, Dignass A, Bokemeyer B, et al; European Crohn's and Colitis Organisation. Second European evidence-based consensus on the diagnosis

and management of ulcerative colitis part 3: special situations. JCrohns Colitis 2013;7:1-33.

69. Gasche C, Waldhoer T, Feichtenschlager T, et al; Austrian Inflammatory Bowel Diseases Study Group. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001;96:2382-2387.

70. Bartels U, Pedersen NS, Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol 1978;13:649-656.

71. Lomer MC, Kodjabashia K, Hutchinson C, Greenfield SM, Thompson RP, Powell JJ. Intake of dietary iron is low in patients with Crohn's disease: a case-control study. Br J Nutr 2004;91:141-148.

72. de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther2005;22:1097-1105.

73. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-1192.

74. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008;121:943-948.

75. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci2002;47:1266-1278.

76. Seril DN, Liao J, West AB, Yang GY. High-iron diet: foe or feat in ulcerative colitis and ulcerative colitis-associated carcinogenesis. JClin Gastroenterol 2006;40:391-397.

77. Lugg S, Beal F, Nightingale P, Bhala N, Iqbal T. Iron treatment and inflammatory bowel disease: What happens in real practice? J Crohns Colitis 2014;8:876-880.

78. Oldenburg B, van Berge Henegouwen GP, Rennick D, Van Asbeck BS, Koningsberger JC. Iron supplementation affects the production of pro-inflammatory cytokines in IL-10 deficient mice. Eur J Clin Invest 2000;30:505-510.

79. Harris ML, Schiller HJ, Reilly PM, Donowitz M, Grisham MB, Bulkley GB. Free radicals and other reactive oxygen metabolites in inflammatory bowel disease: Cause, consequence or epiphenomenon? Pharmacol Ther 1992;53:375-408.

80. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. JCrohns Colitis 2012;6:267-275.

81. Klein R, Herman SP, Bullock BC, Talley FA. Methyl mercury intoxication in rat kidneys. Functional and pathological changes. Arch Pathol 1973;96:83-90.

82. Schröder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-2509.

83. Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011;78:480-491.

84. Evstatiev R, Marteau P, Iqbal T, et al; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141:846-853.e1-e2.

85. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382.

86. Sobrado CW, Cançado RD, Sobrado LF, Frugis MO, Sobrado MF. Treatment of anemia and improvement of quality of life among patients with Crohn's disease: experience using ferric carboxymaltose. Arq Gastroenterol 2015;52:255-259.

87. Kulnigg S, Teischinger L, Dejaco C, Waldhör T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009;104:1460-1467.

88. Evstatiev R, Alexeeva O, Bokemeyer B, et al; FERGI Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol2013;11:269-277.

89. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1982;1:652-655.

90. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. NEngl J Med 1996;334:619-623.

91. Moreno López R, Sicilia Aladrén B, Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009;15:4675-4685.

92. Nakamura S, Sho M, Koyama F, et al. Erythropoietin attenuates intestinal inflammation and promotes tissue regeneration. Scand J Gastroenterol 2015;50:1094-1102.

93. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica2010;95:199-205.

94. Enko D, Wagner H, Kriegshäuser G, et al. Hepcidin-25 vs. conventional clinical biomarkers in the diagnosis of functional iron deficiency. Eur J Haematol 2015;95:507-513.

95. Karlsson T. Mass spectrometry evaluation of the hepcidin-25 assay in the differential diagnosis of iron deficiency anaemia with concurrent inflammation and anaemia of inflammation in elderly patients. Eur J Haematol 2015;95:467-471.

96. Marković M, Majkić-Singh N, Ignjatović S, Singh S. Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. Int J Lab Hematol 2007;29:341-346.

97. Urrechaga E, Borque L, Escanero JF. Percentage of hypochromic erythrocytes as a potential marker of iron availability. Clin Chem Lab Med 2011;50:685-687.

98. Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother2015;16:2859-2867.

99. Levey JA, Barrand MA, Callingham BA, Hider RC. Characteristics of iron(III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol. Biochem Pharmacol 1988;37:2051-2057.

100. Barrand MA, Callingham BA, Dobbin P, Hider RC. Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat. Br J Pharmacol1991;102:723-729.

101. Hashizume M, Uchiyama Y, Horai N, Tomosugi N, Mihara M. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int 2010;30:917-923.

102. Xiao JJ, Krzyzanski W, Wang YM, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J 2010;12:646-657.